Teleflex (TFX) shares moved on Interventional headwinds and the related 2026 revenue guidance revision, while the Q2 beat remains encouraging and 2027 framework is achievable, RBC Capital Markets said in a note emailed Friday.

The company's Q2 beat reflects strong execution in the Vascular and Surgical segments, both of which grew at an above-market high-single-digit pace in H1, the firm highlighted. Management noted that growth will moderate in H2 as Vascular distributor inventories normalize and Surgical faces harder comps, with Q3 seasonality factored in, according to the note.

RBC believes a clear path to durable mid-single-digit growth for Teleflex is important to share performance in the mid-to- long term, which it thinks is achievable.

The company called out three factors, including order-to-cash customer confusion, distributor timing gaps, and sales force transitions with open positions taking nearly 6 months to ramp, which RBC sees as short-term headwinds that are solely integration-related and not indicative of weakness in the underlying product portfolio, the note added.

RBC sees the 2027 framework as achievable and the current pullback as a buying opportunity given earnings power trajectory.

RBC kept an outperform rating on Teleflex with a price target of $155.

Price: 134.15, Change: -4.74, Percent Change: -3.42